Do noradrenaline and serotonin differentially affect social motivation and behaviour?

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major depression is associated with significant impairments in social functioning.
• Selective noradrenaline reuptake inhibitors (NARIs) and selective serotonin reuptake inhibitors (SSRIs) are common antidepressant treatments.
• The differential effects of targeting noradrenergic versus serotonergic systems on social motivation remain an area of investigation.

Purpose of the Study:

• To compare the effects of reboxetine (NARI) and fluoxetine (SSRI) on social motivation and behavior in patients with major depression.
• To evaluate the efficacy of a novel Social Adaptation Self-evaluation Scale (SASS) in assessing treatment-related changes in social functioning.

Main Methods:

• A placebo-controlled, 8-week study involving patients with major depression.
• Participants were randomized to receive reboxetine (n=103), fluoxetine (n=100), or placebo (n=99).
• Social adaptation and behavior were assessed using the 21-item Social Adaptation Self-evaluation Scale (SASS).

Main Results:

• Both reboxetine and fluoxetine groups showed significantly higher mean SASS total scores compared to the placebo group.
• The reboxetine group demonstrated significantly greater improvement in SASS total score compared to the fluoxetine group.
• Analysis indicated that reboxetine was associated with improvements in negative self-perception and lack of motivation, areas where fluoxetine showed less impact.

Conclusions:

• Selective noradrenergic modulation with reboxetine may offer superior benefits for social functioning in major depression compared to selective serotonergic modulation with fluoxetine.
• These findings support the hypothesis of distinct roles for noradrenaline in drive and serotonin in mood regulation.
• The SASS is a sensitive measure for detecting treatment-induced changes in social adaptation in major depressive disorder.